TL;DR
This study investigates the prognostic significance of UBA1 protein expression in breast cancer, finding that elevated UBA1 levels in both tumor and stromal cells are associated with poorer overall survival. The research highlights UBA1's potential as a diagnostic and therapeutic target, particularly in luminal subtypes.
What Problem Does This Paper Address?
Breast cancer is a complex disease with significant heterogeneity, making it challenging to predict treatment failure and personalize therapies. While established prognostic markers exist, there's a continuous need for new biomarkers that can improve diagnostic stratification and identify patients at higher risk. The ubiquitin-proteasome system (UPS) is crucial for cellular homeostasis, and its dysregulation has been linked to various cancers. UBA1, a key enzyme in the UPS, has shown promise as a therapeutic target in other cancers, and preliminary research suggests a link between UBA1 mRNA levels and breast cancer progression. However, the role of UBA1 protein expression, especially across different intrinsic breast cancer subtypes, remains poorly understood. This paper aims to fill that gap by evaluating the prognostic relevance of UBA1 protein expression in a cohort of breast cancer patients.
Methods
The researchers employed a retrospective, single-center study design using formalin-fixed, paraffin-embedded (FFPE) tissue samples from 413 chemotherapy-naïve breast cancer patients. A key methodological innovation was the use of AI-assisted image analysis software (HALO AI) for the computational evaluation of immunohistochemically stained tissue microarrays (TMAs). This approach allowed for precise quantification of UBA1 protein expression in both tumor cells and the surrounding stroma, as well as in different cellular compartments (nucleus and cytoplasm). Standard immunohistochemistry was used to detect UBA1 and intrinsic subtype markers (ER, PgR, HER2, Ki-67). The AI classifier was trained and validated to ensure high accuracy in identifying and quantifying protein expression. Statistical analyses included descriptive statistics, bivariate analysis (chi-squared test, Fisher's exact test, Wilcoxon rank-sum test), Kaplan-Meier estimation with log-rank testing for survival analysis, and univariable and multivariable Cox regression models to assess prognostic significance.
Datasets
The study utilized a dataset of 413 invasive breast cancer tissue samples collected from the Institute of Surgical Pathology at the University Medical Centre Freiburg, Germany. These samples were from chemotherapy-naïve patients treated between 2011 and 2020. Clinicopathological data were also collected for these patients. The paper does not introduce a new benchmark dataset but rather uses a well-defined clinical cohort for its analysis.
Key Insights and Ideas
- UBA1 as a Prognostic Indicator: The study strongly suggests that UBA1 protein expression, both in tumor cells and the tumor microenvironment (stroma), is a significant prognostic factor in breast cancer.
- Stromal UBA1's Role in Microenvironment: Elevated stromal UBA1 expression, particularly in the cytoplasm, is linked to poorer outcomes, especially in luminal subtypes. This points to the tumor microenvironment (TME) playing a crucial role in disease progression, potentially through pro-inflammatory and immunosuppressive mechanisms.
- Tumor Cell UBA1's Independent Prognostic Value: UBA1 expression within tumor cells, especially nuclear expression, was found to be an independent prognostic marker, even after adjusting for other clinicopathological factors.
- Subtype-Specific Effects: The impact of UBA1 expression varies across breast cancer subtypes. While generally associated with worse outcomes, there's a suggestion of a favorable association in HER2-enriched tumors, though this needs further investigation due to small sample size.
- AI-Powered Pathology: The successful application of AI for quantifying protein expression in TMAs demonstrates its potential to enhance the accuracy and efficiency of prognostic marker evaluation in pathology.
Key Results
- High UBA1 expression in both tumor and stromal compartments was significantly associated with reduced overall survival (OS).
- Elevated stromal UBA1 expression was linked to poorer survival in luminal A and luminal B subtypes.
- Increased nuclear UBA1 expression in tumor cells was associated with worse outcomes in the Luminal B subtype.
- Multivariable Cox regression analysis identified UBA1 expression in tumor cells as an independent prognostic marker.
- High stromal UBA1 expression was associated with a broader range of adverse clinicopathological parameters.
- For nuclear UBA1 expression in tumor cells, the 10-year OS was 62% in the high-expression group versus 78% in the low-expression group. Similar trends were observed for stromal UBA1 expression.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-Center Cohort: The study was conducted at a single center, which may introduce selection bias and limit the generalizability of the findings.
- TMA and AI Variability: Potential sources of technical variability from TMA preparation and AI-assisted image analysis cannot be entirely excluded.
Future work suggested includes:
- Multicenter Validation: Prospective, multicenter validation studies are needed to confirm these findings.
- Orthogonal Measurements: Incorporating orthogonal measurements (e.g., CAF activity, NF-kB pathways) would help substantiate the proposed mechanisms.
- Therapeutic Strategies: Further investigation into the therapeutic potential of UBA1 inhibitors, possibly in combination with other treatments like immunotherapy, is warranted, ideally in prospective clinical trials.
- Larger Cohorts for Subtypes: Future studies should utilize larger cohorts, particularly for rarer subtypes like HER2-enriched and triple-negative breast cancer, to better understand UBA1's role in these specific groups.
Summary updated